# A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

> **NCT04328844** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **iOnctura** · enrollment: 210 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Non-Hodgkin Lymphoma, Adult
- NSCLC
- Myelofibrosis
- Uveal Melanoma

## Interventions

- **DRUG:** IOA-244
- **DRUG:** Avelumab Injection
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04328844
- **Lead sponsor:** iOnctura
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-25
- **Primary completion:** 2023-12-13
- **Final completion:** 2027-03
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04328844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04328844, "A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04328844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*